Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13,839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correlation Between Early Endpoints and Overall Survival in Non-Small-Cell Lung Cancer: A Trial-Level Meta-Analysis.
Shameer K, Zhang Y, Jackson D, Rhodes K, Neelufer IKA, Nampally S, Prokop A, Hutchison E, Ye J, Malkov VA, Liu F, Sabin A, Weatherall J, Duran C, Iacona RB, Khan FM, Mukhopadhyay P. Shameer K, et al. Among authors: ye j. Front Oncol. 2021 Jul 26;11:672916. doi: 10.3389/fonc.2021.672916. eCollection 2021. Front Oncol. 2021. PMID: 34381708 Free PMC article.
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, Segal NH, Jin X, Zheng Y, Narwal R, Gupta A, Dennis PA, Ye J, Mukhopadhyay P, Higgs BW, Ranade K. Sridhar S, et al. Among authors: ye j. Clin Lung Cancer. 2019 Nov;20(6):e601-e608. doi: 10.1016/j.cllc.2019.06.020. Epub 2019 Jun 26. Clin Lung Cancer. 2019. PMID: 31327642 Free article. Clinical Trial.
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Si H, Kuziora M, Quinn KJ, Helman E, Ye J, Liu F, Scheuring U, Peters S, Rizvi NA, Brohawn PZ, Ranade K, Higgs BW, Banks KC, Chand VK, Raja R. Si H, et al. Among authors: ye j. Clin Cancer Res. 2021 Mar 15;27(6):1631-1640. doi: 10.1158/1078-0432.CCR-20-3771. Epub 2020 Dec 22. Clin Cancer Res. 2021. PMID: 33355200 Clinical Trial.
Association of PD-L1 Expression on Tumor and Immune Cells with Survival in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Assay Validation.
Wildsmith S, Ye J, Franks A, Melillo G, Armstrong J, Whiteley J, Schnittker K, Lian F, Roland B, Sabalos C, Ahmadi P, Fayette J, Even C, Mesía R, Siu LL, Zandberg DP, Walker J. Wildsmith S, et al. Among authors: ye j. Cancer Res Commun. 2022 Jan 20;2(1):39-48. doi: 10.1158/2767-9764.CRC-21-0032. eCollection 2022 Jan. Cancer Res Commun. 2022. PMID: 36860696 Free PMC article.
Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Wildsmith S, Li W, Wu S, Stewart R, Morsli N, Raja R, Zhang Q, Ye J, He P, Shetty J, Yovine A, Holoweckyj N, Real K, Walker J, Wrona M, de Los Reyes M, Barker C, Whiteley J, Haddad R, Licitra L, Ferris R, Fayette J, Zandberg DP, Siu LL, Mesía R. Wildsmith S, et al. Among authors: ye j. Clin Cancer Res. 2023 Jun 1;29(11):2066-2074. doi: 10.1158/1078-0432.CCR-22-2765. Clin Cancer Res. 2023. PMID: 36806911 Free PMC article. Clinical Trial.
13,839 results
You have reached the last available page of results. Please see the User Guide for more information.